<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04530695</url>
  </required_header>
  <id_info>
    <org_study_id>2020LS118</org_study_id>
    <nct_id>NCT04530695</nct_id>
  </id_info>
  <brief_title>Diagnosis and Treatment of Periodontal Disease in Patients With AML</brief_title>
  <official_title>Early Diagnosis and Treatment of Periodontal Disease in Patients With AML to Reduce Bloodstream Infections During Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 randomized controlled trial of pre-chemotherapy periodontal deep cleaning&#xD;
      in Acute Myelogenous Leukemia (AML) patients with asymptomatic periodontitis.&#xD;
&#xD;
      Once eligibility is confirmed, participants with periodontitis will be randomized in a 1:1&#xD;
      ratio to undergo treatment by scaling and root planing (SRP, &quot;deep cleaning&quot;) (arm A) or&#xD;
      receive no periodontal treatment (arm B). We will compare the incidence of Blood Stream&#xD;
      Infection (BSI) during chemotherapy between the two arms.&#xD;
&#xD;
      Study participation will continue until day 28 of chemotherapy or discharge from hospital,&#xD;
      whichever occurs first.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bloodstream infection (BSI) is common in patients with acute myeloid leukemia (AML) and&#xD;
      causes significant morbidity and mortality. Chemotherapy disrupts oral and intestinal mucosal&#xD;
      barriers, facilitating bacterial translocation to the bloodstream.&#xD;
&#xD;
      Baseline periodontitis is associated with higher risk of BSI during chemotherapy. In AML&#xD;
      patients, since baseline screening and treatment of asymptomatic periodontitis is currently&#xD;
      not a standard practice, the researchers are hoping to (i) personalize supportive care&#xD;
      according to patient-specific risk factors; (ii) promote an interdisciplinary approach to&#xD;
      supportive care by bringing periodontists into the treatment team; (iii) improve quality of&#xD;
      life by reducing hospitalization length; (iv) decrease the incidence of re-hospitalization&#xD;
      during future phases of treatment; (v) decrease early treatment related mortality (TRM); and&#xD;
      (vi) decrease healthcare costs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2022</start_date>
  <completion_date type="Anticipated">November 2026</completion_date>
  <primary_completion_date type="Anticipated">November 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of neutropenic fever (NF) by day 28 of chemotherapy or discharge</measure>
    <time_frame>Day 28 or discharge date (whichever occurs first)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of BSI by day 28 of chemotherapy or discharge</measure>
    <time_frame>Day 28 or discharge date (whichever occurs first)</time_frame>
    <description>Incidence of bloodstream infections by day 28 of chemotherapy or discharge (whichever occurs first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of blood culture-negative NF by day 28 of chemotherapy or discharge, whichever occurs first</measure>
    <time_frame>Day 28 or discharge date (whichever occurs first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of oral mucositis by day 28 of chemotherapy or discharge, whichever occurs first</measure>
    <time_frame>Day 28 or discharge date (whichever occurs first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of death by day 28</measure>
    <time_frame>Day 28 or discharge date (whichever occurs first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days hospitalized</measure>
    <time_frame>Upto 8 weeks</time_frame>
    <description>Hospitalization length</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Neutropenic Fever within 2 days after periodontal examination/treatment (safety endpoint)</measure>
    <time_frame>within 2 days after periodontal examination/treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>AML</condition>
  <condition>Acute Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm A: Deep Cleaning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants with periodontitis will undergo treatment by scaling and root planing (SRP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: No cleaning</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>participants with periodontitis will undergo no periodontal treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Scaling and Root Planing</intervention_name>
    <description>Periodontal treatment by scaling and root planing (SRP), deep cleaning</description>
    <arm_group_label>Arm A: Deep Cleaning</arm_group_label>
    <other_name>SRP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Newly diagnosed or relapsed AML&#xD;
&#xD;
          -  Planned intensive chemotherapy (Any regimen expected to require 3-4 weeks of inpatient&#xD;
             stay)&#xD;
&#xD;
          -  Antibacterial prophylaxis using levofloxacin 500 mg daily&#xD;
&#xD;
          -  Sufficient time to perform periodontal examination and treatment by day 1 of&#xD;
             chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment for AML, except hydroxyurea or leukapheresis&#xD;
&#xD;
          -  ANC &lt;0.5 x 10^9/L at the time of enrollment&#xD;
&#xD;
          -  Post-transfusion platelet count &lt;50x10^9/L at the time of enrollment&#xD;
&#xD;
          -  Unstable for transfer to the School of Dentistry&#xD;
&#xD;
          -  Fever at the time of enrollment&#xD;
&#xD;
          -  Documented infection at the time of enrollment&#xD;
&#xD;
          -  SRP in the last 3 months&#xD;
&#xD;
          -  Symptomatic periodontal disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armin Rashidi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota, Division of Hematology, Oncology and Transplantation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Armin Rashidi, MD, PhD</last_name>
    <phone>612-625-1110</phone>
    <email>arashidi@umn.edu</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>Periodontitis</keyword>
  <keyword>Blood stream infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Periodontal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

